These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

512 related items for PubMed ID: 24426781

  • 21. Risk Factors Associated with a First Exacerbation Among Patients with COPD Classified as GOLD A and B in Routine Clinical Practice in the UK.
    Rothnie KJ, Numbere B, Gelwicks S, Lu Y, Sharma R, Compton C, Ismaila AS, Quint JK.
    Int J Chron Obstruct Pulmon Dis; 2023; 18():2673-2685. PubMed ID: 38022832
    [Abstract] [Full Text] [Related]

  • 22. The Economic Burden of Comorbid Obstructive Sleep Apnea Among Patients with Chronic Obstructive Pulmonary Disease.
    Hong YD, Onukwugha E, Slejko JF.
    J Manag Care Spec Pharm; 2020 Oct; 26(10):1353-1362. PubMed ID: 32996389
    [Abstract] [Full Text] [Related]

  • 23. Risk factors for acute exacerbations of COPD in a primary care population: a retrospective observational cohort study.
    Müllerová H, Shukla A, Hawkins A, Quint J.
    BMJ Open; 2014 Dec 18; 4(12):e006171. PubMed ID: 25524545
    [Abstract] [Full Text] [Related]

  • 24. Cost-effectiveness of available treatment options for patients suffering from severe COPD in the UK: a fully incremental analysis.
    Hertel N, Kotchie RW, Samyshkin Y, Radford M, Humphreys S, Jameson K.
    Int J Chron Obstruct Pulmon Dis; 2012 Dec 18; 7():183-99. PubMed ID: 22500119
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. COPD exacerbation frequency and its association with health care resource utilization and costs.
    Dhamane AD, Moretz C, Zhou Y, Burslem K, Saverno K, Jain G, Renda A, Kaila S.
    Int J Chron Obstruct Pulmon Dis; 2015 Dec 18; 10():2609-18. PubMed ID: 26664109
    [Abstract] [Full Text] [Related]

  • 29. Impact of comorbid conditions in COPD patients on health care resource utilization and costs in a predominantly Medicare population.
    Schwab P, Dhamane AD, Hopson SD, Moretz C, Annavarapu S, Burslem K, Renda A, Kaila S.
    Int J Chron Obstruct Pulmon Dis; 2017 Dec 18; 12():735-744. PubMed ID: 28260880
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Contemporary issues in the care of patients with chronic obstructive pulmonary disease.
    Urbano FL, Pascual RM.
    J Manag Care Pharm; 2005 Jun 18; 11(5 Suppl A):S2-13; quiz S14-6. PubMed ID: 15934804
    [Abstract] [Full Text] [Related]

  • 32. Economic Burden of COPD by Disease Severity - A Nationwide Cohort Study in Denmark.
    Løkke A, Lange P, Lykkegaard J, Ibsen R, Andersson M, de Fine Licht S, Hilberg O.
    Int J Chron Obstruct Pulmon Dis; 2021 Jun 18; 16():603-613. PubMed ID: 33731990
    [Abstract] [Full Text] [Related]

  • 33. Eosinophil counts in first COPD hospitalizations: a 1-year cost analysis in Quebec, Canada.
    Poder TG, Carrier N, Bélanger M, Couillard S, Courteau J, Larivée P, Vanasse A.
    Int J Chron Obstruct Pulmon Dis; 2018 Jun 18; 13():3065-3076. PubMed ID: 30349220
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. A longitudinal, retrospective cohort study on the impact of roflumilast on exacerbations and economic burden among chronic obstructive pulmonary disease patients in the real world.
    Wan Y, Sun SX, Corman S, Huang X, Gao X, Shorr AF.
    Int J Chron Obstruct Pulmon Dis; 2015 Jun 18; 10():2127-36. PubMed ID: 26504378
    [Abstract] [Full Text] [Related]

  • 36. Healthcare, Medication Utilization and Outcomes of Patients with COPD by GOLD Classification in England.
    Sansbury LB, Rothnie KJ, Bains C, Compton C, Anley G, Ismaila AS.
    Int J Chron Obstruct Pulmon Dis; 2021 Jun 18; 16():2591-2604. PubMed ID: 34552325
    [Abstract] [Full Text] [Related]

  • 37. Clinical factors and comorbidities affecting the cost of hospital-treated COPD.
    Deniz S, Şengül A, Aydemir Y, Çeldir Emre J, Özhan MH.
    Int J Chron Obstruct Pulmon Dis; 2016 Jun 18; 11():3023-3030. PubMed ID: 27980399
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. The costs of exacerbations in chronic obstructive pulmonary disease (COPD).
    Andersson F, Borg S, Jansson SA, Jonsson AC, Ericsson A, Prütz C, Rönmark E, Lundbäck B.
    Respir Med; 2002 Sep 18; 96(9):700-8. PubMed ID: 12243316
    [Abstract] [Full Text] [Related]

  • 40. Prevalence and burden of breathlessness in patients with chronic obstructive pulmonary disease managed in primary care.
    Müllerová H, Lu C, Li H, Tabberer M.
    PLoS One; 2014 Sep 18; 9(1):e85540. PubMed ID: 24427316
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 26.